Global Antibody Drug Conjugates Market Overview
Antibody-drug conjugates (ADC) are an innovative therapeutic approach that combines monoclonal antibodies' unique, high specificity, properties, and anti-tumor activity (mAbs). Antibody-drug conjugates (ADCs) are becoming increasingly prominent in the oncology landscape. These cytotoxic agents kill cancer cells and a chemical linker to attach the cytotoxic agent to the antibody. ADCs work by targeting a particular cell population without harming the other cells. The key highlights of antibody-drug conjugates include a monoclonal antibody, a stable linker, and a cytotoxic agent to target various cancers. Antibody-drug conjugates are wholly meant for cancer treatment. In recent years, cancer prevalence has grown, resulting in a parallel requirement for therapeutics. Cancer is a leading cause of death globally. In 2020, it accounted for about 10 million deaths. The most common new cancer cases were breast, lung, colon and rectum, prostate, skin, and stomach. The prevalence is projected to rise with the growing aging population and increasing consumption of tobacco and alcohol.
According to Value Market Research, the global antibody-drug conjugates market size was valued at about USD 3.2 billion in 2020 and is estimated to grow at a CAGR of around 26% during the forecast period 2021 to 2027.
Antibody-drug conjugates are gaining robust attention potential increased activity and reduced toxicity compared with traditional chemotherapies. Also, food and drug administration (FDA) approval to the companies for antibody-drug conjugates is further fuelling the market growth. To date, ten antibody-drug conjugates have received market approval, and nearly 100 investigational ADCs are presently in pre-clinical and clinical trials. In addition, the growing collaborations between research institutes and biotechnology and biopharmaceutical companies are also expected to boost market growth in upcoming years. However, the high cost of procedures, presence of other conventional treatment such as chemotherapy, radiotherapy, lack of fund is anticipated to limit the market growth.
The global antibody-drug conjugates market is comprised of giant players. F. Hoffman-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Seattle Genetics Inc., Genentech Inc., Immunogen Inc., Immunomedics, Inc., Progenics Pharmaceuticals Inc., and Bayer Healthcare Pharmaceuticals are vital players associated with the market.
In this research report, the global antibody-drug conjugates market is segmented by type, application, and region.
Analysis, By Types
Based on types, the global antibody-drug conjugates market is monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are most promising for antibody-drug conjugates. It possesses modest antitumor efficacy as a single agent. Monoclonal antibodies have been identified to show promising effects in a vast number of cancers. The monoclonal antibodies segment is estimated to grow at a high pace during the forecast period. Growing approvals and clinical trials are anticipated to trigger segment growth.
Analysis, By Application
Based on application, the global antibody-drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, others. Breast cancer was the leading segment in 2020 and is likely to witness considerable growth over the forecast period. Antibody-drug conjugates are widely adopted for breast cancer treatment due to their effectiveness. Growing research efforts to identify novel targets and combination with other treatment modalities will further raise demand.
Analysis, By Region
Based on region, the global antibody-drug conjugates market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominated the global antibody-drug conjugates market. North America has a strong pharmaceutical & healthcare infrastructure and is home to many prominent players and end-users. The rising prevalence of disease, easy access to treatment, and growing investment in cancer therapy research drive regional growth. As per National Cancer Institute Statistics, in 2020, an estimated 1,806,590 new cancer cases were diagnosed in the US, and 606,520 people died from the disease. Regional players are adopting collaboration strategies to gain access to more detailed research and a high success rate.
Market Segmentation covered in the Report:
- Monoclonal Antibodies
- Blood Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumour
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.